Recurrent Childhood Cerebellar Astrocytoma
23
0
0
19
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.0%
3 terminated out of 23 trials
86.4%
-0.1% vs benchmark
0%
0 trials in Phase 3/4
21%
4 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (23)
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Irinotecan in Treating Children With Refractory Solid Tumors
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas